healthcare
healthcare Articles
The August 31 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks increased.
Published:
After Satsuma Pharmaceuticals reported disappointing late-stage results from its migraine treatment, and its shares were absolutely crushed Thursday morning.
Published:
The FDA has approved Innoviva's treatment of asthma and for patients with chronic obstructive pulmonary disease, the company announced, giving shares a boost early Thursday.
Published:
Practically any biotech company attempting almost anything COVID-19 related has seen massive gains. However, there is likely more to come for the rest of the year and into next year. These five...
Published:
iBio has announced that it has selected a vaccine to advance for the prevention of infection by the coronavirus that causes COVID-19.
Published:
There is no cure for mesothelioma, but some companies are looking for better ways to treat the disease.
Published:
Intra-Cellular Therapies was one of the biggest winners on Wednesday after the company announced positive results from its late-stage clinical trial in patients with bipolar disorder.
Published:
A key update from the FDA on its treatment for relapsed/refractory multiple myeloma boosted Precision BioSciences shares early on Wednesday.
Published:
Co-Diagnostics announced Tuesday that it has entered into an agreement with Arches Research to expand Arches' COVID-19 testing services using Co-Diagnostics’ test kit.
Published:
Kamada has announced initial interim results from its ongoing midstage coronavirus study of its treatment of COVID-19 patients with pneumonia.
Published:
Corbus Pharmaceuticals has reported that its systemic sclerosis study failed to reach the endpoints, and investors were not pleased.
Published:
On Thursday, Akebia Therapeutics Inc. (NASDAQ: AKBA) announced topline results from the Phase 3 PRO2TECT studies evaluating the safety and efficacy of vadadustat in chronic kidney disease (CKD)....
Published:
Auris Medical has reported topline data from its Phase 2 Travers trial with intranasal betahistine in vertigo.
Published:
Jounce Therapeutics Inc. (NASDAQ: JNCE) made a massive gain on Tuesday after the company announced a licensing agreement with Gilead Sciences Inc. (NASDAQ: GILD). This deal is for the discovery and...
Published:
A recent final ruling from the U.S. Drug Enforcement Administration has cast doubt on the legality of some non-psychoactive products derived from the hemp.
Published:
Last Updated: